At week 52 , canagliflozin 100 and 300 mg reduced HbA1c compared with placebo ( -0.19 , -0.33 and 0.07 % , respectively ) ; placebo-subtracted differences ( 95 % confidence interval ) were -0.27 % ( -0.53 , 0.001 ) and -0.41 % ( -0.68 , -0.14 ) .